Gencurix Inc (229000) - Net Assets
Based on the latest financial reports, Gencurix Inc (229000) has net assets worth ₩9.20 Billion KRW (≈ $6.23 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩24.88 Billion ≈ $16.86 Million USD) and total liabilities (₩15.69 Billion ≈ $10.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Gencurix Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩9.20 Billion |
| % of Total Assets | 36.96% |
| Annual Growth Rate | 7.74% |
| 5-Year Change | -72.09% |
| 10-Year Change | N/A |
| Growth Volatility | 11346.84 |
Gencurix Inc - Net Assets Trend (2016–2024)
This chart illustrates how Gencurix Inc's net assets have evolved over time, based on quarterly financial data. Also explore 229000 total assets for the complete picture of this company's asset base.
Annual Net Assets for Gencurix Inc (2016–2024)
The table below shows the annual net assets of Gencurix Inc from 2016 to 2024. For live valuation and market cap data, see 229000 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩14.90 Billion ≈ $10.10 Million |
+24.10% |
| 2023-12-31 | ₩12.00 Billion ≈ $8.13 Million |
+85.37% |
| 2022-12-31 | ₩6.48 Billion ≈ $4.39 Million |
-79.11% |
| 2021-12-31 | ₩30.99 Billion ≈ $21.00 Million |
-41.94% |
| 2020-12-31 | ₩53.38 Billion ≈ $36.17 Million |
+34296.58% |
| 2019-12-31 | ₩155.18 Million ≈ $105.16K |
-98.31% |
| 2018-12-31 | ₩9.20 Billion ≈ $6.23 Million |
+43.61% |
| 2017-12-31 | ₩6.41 Billion ≈ $4.34 Million |
-21.92% |
| 2016-12-31 | ₩8.20 Billion ≈ $5.56 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Gencurix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7128969911000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩7.90 Billion | 53.04% |
| Other Components | ₩95.84 Billion | 643.34% |
| Total Equity | ₩14.90 Billion | 100.00% |
Gencurix Inc Competitors by Market Cap
The table below lists competitors of Gencurix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eurotel SA
WAR:ETL
|
$25.58 Million |
|
System1 Inc
NYSE:SST
|
$25.59 Million |
|
Adore Beauty Group Ltd
AU:ABY
|
$25.60 Million |
|
Zenith Minerals Ltd
AU:ZNC
|
$25.60 Million |
|
Ranix INC
KQ:317120
|
$25.55 Million |
|
Data I/O Corporation
NASDAQ:DAIO
|
$25.54 Million |
|
Allbirds Inc
NASDAQ:BIRD
|
$25.54 Million |
|
Gumho NT Co Ltd
KQ:130500
|
$25.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gencurix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,776,121,530 to 14,896,659,420, a change of 1,120,537,890 (8.1%).
- Net loss of 3,626,192,470 reduced equity.
- Share repurchases of 6,937,316,880 reduced equity.
- New share issuances of 6,937,316,870 increased equity.
- Other factors increased equity by 4,746,730,370.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-3.63 Billion | -24.34% |
| Share Repurchases | ₩6.94 Billion | -46.57% |
| Share Issuances | ₩6.94 Billion | +46.57% |
| Other Changes | ₩4.75 Billion | +31.86% |
| Total Change | ₩- | 8.13% |
Book Value vs Market Value Analysis
This analysis compares Gencurix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.60x to 2.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1461.39 | ₩2340.00 | x |
| 2017-12-31 | ₩1078.73 | ₩2340.00 | x |
| 2018-12-31 | ₩1406.54 | ₩2340.00 | x |
| 2019-12-31 | ₩28.78 | ₩2340.00 | x |
| 2020-12-31 | ₩8341.56 | ₩2340.00 | x |
| 2021-12-31 | ₩4295.08 | ₩2340.00 | x |
| 2022-12-31 | ₩882.60 | ₩2340.00 | x |
| 2023-12-31 | ₩1001.96 | ₩2340.00 | x |
| 2024-12-31 | ₩942.71 | ₩2340.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gencurix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -70.63%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 2.02x
- Recent ROE (-24.34%) is above the historical average (-753.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -110.48% | -1547.25% | 0.06x | 1.13x | ₩-9.88 Billion |
| 2017 | -106.46% | -101319.51% | 0.00x | 1.15x | ₩-7.46 Billion |
| 2018 | -62.23% | -2268.73% | 0.02x | 1.10x | ₩-6.64 Billion |
| 2019 | -5904.25% | -6706.45% | 0.06x | 15.39x | ₩-9.18 Billion |
| 2020 | 62.03% | 2106.14% | 0.02x | 1.20x | ₩27.77 Billion |
| 2021 | -111.87% | -1137.86% | 0.06x | 1.78x | ₩-37.77 Billion |
| 2022 | -379.86% | -961.01% | 0.07x | 5.75x | ₩-25.24 Billion |
| 2023 | -139.81% | -740.68% | 0.08x | 2.43x | ₩-20.64 Billion |
| 2024 | -24.34% | -70.63% | 0.17x | 2.02x | ₩-5.12 Billion |
Industry Comparison
This section compares Gencurix Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $34,406,469,996
- Average return on equity (ROE) among peers: -55.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gencurix Inc (229000) | ₩9.20 Billion | -110.48% | 1.71x | $25.56 Million |
| NSN Co. Ltd (031860) | $59.75 Billion | -53.11% | 0.11x | $8.50 Million |
| JOONGANG DNM Co.Ltd (051980) | $31.75 Billion | -26.44% | 0.25x | $144.40 Million |
| GeneMatrix Inc (109820) | $11.06 Billion | -13.29% | 0.60x | $27.26 Million |
| Genoray Co. Ltd (122310) | $44.97 Billion | 21.06% | 0.30x | $38.45 Million |
| Green Cross Lab Cell Corporation (144510) | $48.10 Billion | 4.84% | 0.13x | $241.86 Million |
| Optipharm.CO.LTD (153710) | $29.01 Billion | -7.05% | 0.42x | $51.60 Million |
| Cytogen Inc (217330) | $475.51 Million | -451.97% | 9.64x | $92.24 Million |
| P&K Skin Research Center Co. Ltd (347740) | $15.96 Billion | 24.33% | 0.11x | $48.83 Million |
| Access Bio Inc (950130) | $68.58 Billion | 3.55% | 0.15x | $125.38 Million |
About Gencurix Inc
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detecti… Read more